盎格鲁力学 ANGO 深 沪
等待开盘 04-01 09:30:00 美东时间
11.37
+0.500
+4.60%
华盛通- 最 高11.4103
- 今 开10.95
- 成交量 48.86万股
- 最 低 10.90
- 昨 收 10.87
- 总市值 4.69亿
- 52周最高 13.99
- 市盈率 静 --
- 换手率 1.19%
- 52周最低 8.36
- 委 比 -12.41%
- 总股本 4121.74万
- 历史最高 32.00
- 量 比 1.09
- 振 幅 4.69%
- 历史最低 5.26
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tilray Q3 earnings: What to expect
Tilray (TLRY) is expected to report an 8% jump in its revenue during its third-quarter results on March 31, before the market opens. The consensus EPS Estimate is $0.07, while revenue is expected to c...
03-31 22:34
T1 Energy misses top-line and bottom-line estimates; introduces FY26 outlook
T1 Energy press release (TE): Q4 GAAP EPS of -$0.70 misses by $0.69. Revenue of $358.55M (vs. $2.94M Y/Y) misses by $9.65M. As of December 31, 2025, T1 had cash, cash equivalents, and restricted cash ...
03-31 18:06
Earnings Snapshot: Virgin Galactic posts mixed Q4 print
Seeking Alpha More on Virgin Galactic Virgin Galactic: Cash Runway Falls Short Of Its Commercialization Timeline Virgin Galactic GAAP EPS of -$0.98 beats by $0.07, revenue of $0.31M misses by $0.1...
03-31 04:19
Terrestrial Energy Inc. GAAP EPS of -$0.39
Terrestrial Energy Inc. press release (IMSR): FY GAAP EPS of -$0.39. As of December 31, 2025, the company held approximately $298 million in cash and short-term investments. 2026 Outlook: The Company ...
03-30 19:08
Nike earnings preview: Investors look for signs of a turnaround
Nike is due to report fiscal third-quarter results after the close on March 31, with Wall Street analysts expecting revenue of $11.2B and EPS of $0.28, down from last year's mark of $0.54. Key themes ...
03-30 18:30
AngioDynamics Expands European Indications For NanoKnife System To Include Soft Tissue Ablation For Tumors Of Liver, Pancreas, Kidney, And Prostate
Growing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Option for Major Solid Tumor TypesAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company
02-19 21:43
AngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors
AngioDynamics expands NanoKnife indications in Europe for liver, pancreas, kidney and prostate tumors AngioDynamics Inc. announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients wit
02-19 21:31
EU expands AngioDynamics NanoKnife indications for multi-organ tumor ablation
EU expands AngioDynamics NanoKnife indications for multi-organ tumor ablation AngioDynamics Inc. said European indications for its NanoKnife System have been expanded to include soft tissue ablation for tumors of the liver, pancreas, kidney and prostate, including use in patients with intermediate-r
02-19 21:31
AngioDynamics Secures FDA IDE Approval and Expanded 510(k) Clearance for AlphaVac System
AngioDynamics Secures FDA IDE Approval and Expanded 510(k) Clearance for AlphaVac System AngioDynamics Inc. announced that it received FDA approval in November 2025 for its Investigational Device Exemption (IDE) application for the APEX-Return pivotal study. This study will evaluate the safety and e
02-03 21:02
FDA genehmigt IDE-Antrag von AngioDynamics für APEX-Return-Studie
FDA genehmigt IDE-Antrag von AngioDynamics für APEX-Return-Studie AngioDynamics Inc. hat im November 2025 die Genehmigung der US-amerikanischen Food and Drug Administration (FDA) für den IDE-Antrag zur APEX-Return-Studie erhalten. In der Studie wird die Sicherheit und Wirksamkeit des AlphaReturn Blo
02-03 21:02
